Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ASE Technology Holding Co Ltd (ASX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ASE Technology Holding Co Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while ASE Technology Holding Co Ltd trades at $40.25 (market cap $89.31B). The key difference: ASE Technology Holding Co Ltd is far larger — about 19.9× ACADIA Pharmaceuticals Inc.'s market cap, and ASE Technology Holding Co Ltd pays a 1.05% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ASX | |
|---|---|---|
Market Cap | $4.49B | $89.31B |
Sector | Health | Technology |
52-Week High | $28.06 | $45.12 |
52-Week Low | $20.06 | $9.50 |
Enterprise Value | $3.69B | $93.75B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ASE Technology Holding (ASX) trades at $39.65, down 5.3% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong quarterly earnings beats, with Q1 2026 EPS of $0.20 beating expectations of $0.1703. Revenue grew to $645.39B in 2025, with net income of $40.02B, while valuation ratios like P/E of 67.98 and P/B of 8.67 suggest premium pricing. Recent news highlights AI-driven demand boosting its LEAP advanced packaging business, with 2026 revenue projected above $3.5B.
Outlook remains positive due to AI infrastructure growth and margin expansion, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is 80% buy, with institutional sentiment buoyed by earnings momentum, though the stock's recent decline may reflect profit-taking after a 77.1% three-month surge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →
